Lundbeck neurology news

H. Lundbeck filed an appeal in the EU General Court of a June 19 decision from the European Commission to fine Lundbeck €93.8 million ($124 million) for anticompetitive activity related to Lundbeck's antidepressant Celexa citalopram. The commission ruled that Lundbeck's deals with four generic companies for the selective serotonin reuptake inhibitor (SSRI) violated competition law. ...